Home › Compare › EFTRW vs RYLD

EFTRW vs RYLD: Dividend Comparison 2026

EFTRW yields 333333.33% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EFTRW wins by $8.099219044190773e+31M in total portfolio value
10 years
EFTRW
EFTRW
● Live price
333333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.099219044190773e+31M
Annual income
$80,944,421,463,343,720,000,000,000,000,000,000,000.00
Full EFTRW calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — EFTRW vs RYLD

📍 EFTRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEFTRWRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EFTRW + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EFTRW pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFTRW
Annual income on $10K today (after 15% tax)
$28,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, EFTRW beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFTRW + RYLD for your $10,000?

EFTRW: 50%RYLD: 50%
100% RYLD50/50100% EFTRW
Portfolio after 10yr
$4.0496095220953863e+31M
Annual income
$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr
Blended yield
99.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EFTRW right now

EFTRW
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-13.6
Piotroski
2/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFTRW buys
0
RYLD buys
0
No recent congressional trades found for EFTRW or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEFTRWRYLD
Forward yield333333.33% ✓12.14%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.099219044190773e+31M$44.5K ✓
Annual income after 10y$80,944,421,463,343,720,000,000,000,000,000,000,000.00 ✓$2,587.35
Total dividends collected$8.098906375781879e+31M$18.8K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: EFTRW vs RYLD ($10,000, DRIP)

YearEFTRW PortfolioEFTRW Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$33,344,033$33,333,333.33$11,914$1,213.65+$33.33M → EFTRW
2$103,911,171,366$103,875,493,250.26$14,099$1,351.30+$103911.16M → EFTRW
3$302,644,656,190,810$302,533,471,237,448.00$16,580$1,494.55+$302644656.17M → EFTRW
4$823,817,797,451,856,400$823,493,967,669,732,100.00$19,384$1,642.61+$823817797451.84M → EFTRW
5$2,095,836,995,961,804,000,000$2,094,955,510,918,530,000,000.00$22,535$1,794.70+$2095836995961804.00M → EFTRW
6$4,983,251,920,823,462,000,000,000$4,981,009,375,237,783,000,000,000.00$26,063$1,950.00+$4983251920823461888.00M → EFTRW
7$11,073,835,968,753,321,000,000,000,000$11,068,503,889,198,040,000,000,000,000.00$29,995$2,107.69+$1.1073835968753322e+22M → EFTRW
8$22,999,277,308,531,336,000,000,000,000,000$22,987,428,304,044,770,000,000,000,000,000.00$34,361$2,266.99+$2.2999277308531335e+25M → EFTRW
9$44,643,905,199,991,210,000,000,000,000,000,000$44,619,295,973,271,085,000,000,000,000,000,000.00$39,194$2,427.12+$4.464390519999121e+28M → EFTRW
10$80,992,190,441,907,720,000,000,000,000,000,000,000$80,944,421,463,343,720,000,000,000,000,000,000,000.00$44,525$2,587.35+$8.099219044190773e+31M → EFTRW

EFTRW vs RYLD: Complete Analysis 2026

EFTRW — Stock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Full EFTRW Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this EFTRW vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFTRW vs SCHDEFTRW vs JEPIEFTRW vs OEFTRW vs KOEFTRW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.